Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
22 participants
INTERVENTIONAL
2005-10-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Medium Chain Triglyceride Consumption on Appetite
NCT01952977
Hormonal Control of Energy and Macronutrient Intake in Obesity (MEMORY)
NCT06752967
Time Restricted Eating for Metabolic and Psychological Optimization
NCT05997316
Weight Regain After Consumption of Food Supplement and Interventional Diet Program
NCT03554525
Glycogen and Appetite
NCT05417659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Bray et al. (2002) has shown a sustained weight loss of \~6 kg over a 9 month period where one-third of a fat-reduced diet (25% fat) was replaced by olestra. This weight loss can not solely be explained by the decreased caloric content of olestra. Thus, inhibition of appetite leading to lower food intake, may be a potential mechanism of the observed weight loss.
A reduced absorption of LCF leaves undigested fatty acids in the middle and lower intestine, which may generate increased feelings of satiety and decrease caloric intake due to regulating peptides and hormones such (CCK, GLP-1, etc.). In addition, intraduodenal fatty acids may also promote distension of the stomach and distension of the intestine, which are well-known gastrointestinal signals controlling mechanisms for food intake.
Taken together, in addition to the acute reduction in caloric intake, LCF may encourage a gastrointestinal hormone response promoting beneficial effects on appetite regulation and energy balance.
Aims To evaluate the short-term effects of LCF on
Primary:
* Appetite sensations after a meal (VAS)
* Postprandiel secretion of appetite regulating hormones
* Ad libitum caloric intake 4,5-h subsequent to a fixed meal
Secondary:
• Palatability of the test meal
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SALATRIM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal weigh, e.i. BMI between 18,5-25 kg/m2
* age 18-40 years
Exclusion Criteria
* gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease
* smoking
* consumption of more than 21 alcoholic drinks/week
* elite athletes
* on mediation
* diet supplements
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danisco
INDUSTRY
University of Copenhagen
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arne Astrup, Proffessor
Role: PRINCIPAL_INVESTIGATOR
Department of human nutrition, The Royal Veterinary and Agricultural University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Human Nutrition, The Royal Veterinary and Agricultural University
Frederiksberg C, Copenhagen, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B218
Identifier Type: -
Identifier Source: secondary_id
(KF) 01 275625
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.